Start Recovering Now
Enhances Stroke Recovery and Supports
Neurological Functions
Stroke has a devastating impact on million of lives
Stroke is the leading cause of adult disability worldwide
• A stroke occurs every 2 seconds
• 15 Million strokes per year (2/3 only partial recovery)
Patients are left without a treatment
• Neuroprotective agents have not (yet) delivered their promise
• Hyper acute intravenous thrombolysis available only to a minority of
patients
• Lack of pharmacological modalities to support post stroke recovery
• Patients grow desperate and frustrated
Interest to look at new sources of therapeutics
• Biopharmaceutical company incorporated in 2003 • By a group of renown scientists from east and west and businessmen. • Focus on safety, quality and clinical data • Offices in Singapore and Paris • Important involvement & initiative of academic/key opinion leaders & clinicians.
SCIENTIFIC ADVISORY BOARD, MEDICAL EXPERTS AND INVESTIGATORS
TCM understanding, Biology and EBM expertise,
Georges Charpak
Nobel Laureate Etienne Beaulieu
Former President,
French Academy
of Sciences
Michel Lazdunski
Director Pharmacology,
CNRS
Acad. Shi Xuemin
Tianjin First Teaching
Hospital of TCM
Acad Han Ji Sheng
Beijing
Neuroscience Inst.
Prof. Zhao Guo Ping
Shanghai Genome
Center
MG Bousser
Advisor on Stroke and
Migraine(France)
Pr Geoffrey Donnan
National Stroke
Institute, University of
Melbourne, Australia
Dr Christopher CHEN
Singapore
National University of
Singapore
“Moleac introduced in the
market NeuroAiD™, the first
treatment that brings faster and
fuller recovery for stroke
patients...”
“Moleac receives the Frost &
Sullivan Asia Pacific Excellence in
Healthcare Award for the success
of its stroke treatment drug
NeuroAiD™...”
Awards recognitions
NeuroAiD™ treatment
Introduction to NeuroAiD™
• NeuroAiD™ is a post stroke recovery medicine for faster and fuller neurological
recovery
• It aids in recovering your independence and reducing neurological deficits
• Effective at early and late stage of stroke as an add-on treatment
• Strong clinical data on efficacy and safety
• 0.5 million patients in 25 countries
Details
• 3 months treatment recommended . Results usually observed within one month
• Capsule form - (can be opened and diluted in water or administrated via gastric tube)
• NeuroAiD™ should be initiated as soon as possible post stroke and it has shown to be
effective up to at least 6 months post stroke.
Aimed at long term reduction of disabilities after a stroke
How NeuroAiD™ improves
SPEECH – case study in
European Neurology journal
reports several improvements
of vision disabilities, with
resolution of anomia and
aphasia.
MOTOR – Stroke publication
reports that patients on
NeuroAiD™ showed a 25%
higher recovery in motor
deficits after one month
treatment.
VISION – case study in
European Neurology journal
reports several improvements
of vision disabilities, with
resolution of diplopia and
hemianopia.
Clinical trials and number of case reports
demonstrated improvements in :
- Motor functions,
- Speech (anomia, aphasia)
- Vision (hemianopia, diplopia)
- Other cognitive.
Introduction to NeuroAiD™
Footage
• NeuroAiD™ commercialization is pursued through a network of affiliates
• In the European Union our subsidiaries in Paris prepare the registration
• We are pursuing exponential geographic expansion
2007 2008 2009 2010 2011
Singapore Malaysia Pakistan Argentina
Iran
Jordan
Lebanon
Iraq
Thailand Philippines
Vietnam
Indonesia
Algeria
Russia
Mexico
Lebanon
Europe
Eastern Europe
CIS
USA
Middle-East
Korea…
NeuroAiD™ in stroke treatment
NeuroAiD™ has shown efficacy in acute and late post-stroke stage.
4 - 5 hours First day 1 week 6 months
Hyper acute therapies such as: rTPA
Window to start the treatment with NeuroAiD™
Acute stage Late stage
Stroke onset
24 hours
Rehabilitation
Publications
Medical marketing – Publications
Scientific publications
• 7 recent publications summarize NeuroAiD™’s efficacy data, pharmacology data and excellent
tolerability :
– Neuropharmacology in 2010 – Pharmacology data
– Cerebrovascular Diseases in 2010 - Safety data in acute stage
– Cerebrovascular Diseases TIERS in 2009 – Pilot study
– Stroke Journal in 2009 – Efficacy trial
– European Neurology in 2008 – Case report
– Cerebrovascular Diseases in 2008 – Safety trial
– The International Journal of Stroke in 2009 – The CHIMES
protocol
Summary of existing clinical evidence
• Pharmacological data show neuroproliferative, neuroregenerative and
neuroprotective properties
• Patients on NeuroAiD™ had 2.4 times more chances to achieve independence
after one month of treatment
• Patients on NeuroAiD™ showed a 25% higher recovery in the motor components
• Many studies and case reports (even at late stage of stroke onset) show good
recovery in motor function, balance, visual and speech functions for patients taking
NeuroAiD™
•NeuroAiD™ does not modify hematological, hemostatic, and biochemical and
ECG parameters in normal subjects and stroke patients
Clinical Trials
14
Clinical trials
Clinical trials
CHIMES sites
R & D
Clinicians leading the CHIMES trial
Prof MG BOUSSER
Hôpital Lariboisière
France
Prof. Geoffrey DONNAN National Stroke Institute – University of Melbourne Australia
Prof David MACHIN CTERU Singapore
Prof Christophe TZOURIO Paris - France
DMSB
Dr Christopher CHEN
National University
Singapore
CTERU (academic CRO) Dr Tan Say Beng Clinical Trials and Epidemiology Research Unit
4 Centres recruiting: University of Santo Tomas, Jose Reyes Medical Centre, Davao Medical Center; Philippines General Hospital Prof Jose NAVARRO, Dr Alejandro C. BAROQUE, Dr Hil Gan, Dr Annabelle Lao Dr Carlos I Chua (PI) Dr Cristina M San Jose
All 4 centres: NUH SGH, TTSH, CGH Dr N.V. RAMANI, Dr Sherry Young, Dr. Bernard CHAN, Dr CHANG Hui Meng Dr Rajinder Singh
SINGAPORE PHILIPPINES
5 Centres Siriraj Hospital Chiangmai University Hospital Chulalongkorn Hospital King Mongkutla Hospital Thammasat Hospital
THAILAND
Prof Niphon Poungvarin Dr Siwaporn Chankrachang Dr Nijasri Suwanwela, Dr Samart Nidhinandana Dr Sombat Muengtaweepongsa
More centres in discussion in • Pakistan • Indonesia • Malaysia • Hong Kong
� Chimes provides an important platform
� Access to leading clinicians / further data on NeuroAiD™ when started within 72h after stroke onset
SRI LANKA
Dr Asita da Silva University of Kelaniya
Thank You
Find out more
www.neuroaid.com